Risk Factors for Bleeding After Endoscopic Submucosal Dissection for Gastric Cancer in Elderly Patients Older Than 80 Years in Japan. by SUGIMOTO Mitsushige et al.
Risk Factors for Bleeding After Endoscopic
Submucosal Dissection for Gastric Cancer in
Elderly Patients Older Than 80 Years in Japan.
著者 SUGIMOTO Mitsushige, HATTA Waku, TSUJI Yosuke,
YOSHIO Toshiyuki, YABUUCHI Yohei, HOTEYA Shu,
DOYAMA Hisashi, NAGAMI Yasuaki, HIKICHI
Takuto, KOBAYASHI Masakuni, MORITA Yoshinori,
SUMIYOSHI Tetsuya, IGUCHI Mikitaka, TOMIDA
Hideomi, INOUE Takuya, MIKAMI Tatsuya,
HASATANI Kenkei, NISHIKAWA Jun, MATSUMURA
Tomoaki, NEBIKI Hiroko, NAKAMATSU Dai, OHNITA
Ken, SUZUKI Haruhisa, UEYAMA Hiroya, HAYASHI
Yoshito, MURATA Masaki, YAMAGUCHI Shinjiro,
MICHIDA Tomoki, YADA Tomoyuki, ASAHINA
Yoshiro, NARASAKA Toshiaki, KURIBAYASHI Shiko,
KIYOTOKI Shu, MABE Katsuhiro, FUJISHIRO
Mitsuhiro, MASAMUNE Atsushi, KAWAI Takashi
journal or
publication title







This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY),
which permits unrestricted use,






































Risk Factors for Bleeding After Endoscopic Submucosal
Dissection for Gastric Cancer in Elderly Patients Older
Than 80 Years in Japan
Mitsushige Sugimoto, MD, PhD1,2, Waku Hatta, MD, PhD3, Yosuke Tsuji, MD, PhD4, Toshiyuki Yoshio, MD, PhD5,
Yohei Yabuuchi, MD, PhD6, Shu Hoteya, MD, PhD7, Hisashi Doyama, MD, PhD8, Yasuaki Nagami, MD, PhD9,
Takuto Hikichi, MD, PhD10, Masakuni Kobayashi, MD, PhD11, Yoshinori Morita, MD, PhD12,13, Tetsuya Sumiyoshi, MD14,
Mikitaka Iguchi, MD, PhD15, Hideomi Tomida, MD16,17, Takuya Inoue, MD, PhD18, Tatsuya Mikami, MD, PhD19,
Kenkei Hasatani, MD, PhD20, Jun Nishikawa, MD, PhD21, Tomoaki Matsumura, MD, PhD22, Hiroko Nebiki, MD, PhD23,
Dai Nakamatsu, MD24, Ken Ohnita, MD, PhD25, Haruhisa Suzuki, MD, PhD26, Hiroya Ueyama, MD, PhD27,
Yoshito Hayashi, MD, PhD28, Masaki Murata, MD2,29, Shinjiro Yamaguchi, MD, PhD30, Tomoki Michida, MD, PhD31,32,
Tomoyuki Yada, MD33, Yoshiro Asahina, MD, PhD34, Toshiaki Narasaka, MD, PhD35, Shiko Kuribayashi, MD, PhD36,
Shu Kiyotoki, MD, PhD37, Katsuhiro Mabe, MD, PhD38, Mitsuhiro Fujishiro, MD, PhD39, Atsushi Masamune, MD, PhD3 and
Takashi Kawai, MD, PhD1
INTRODUCTION: As the aging of people in a society advances, the number of elderly patients older than 80 years in
Japan with gastric cancer continues to increase. Although delayed ulcer bleeding is a major
adverse event after endoscopic submucosal dissection (ESD), little is known about
characteristic risk factors for bleeding in elderly patients undergoing ESD. This study aimed to
evaluate risk factors for delayed bleeding after ESD for gastric cancer in elderly patients older
than 80 years.
METHODS: We retrospectively evaluated the incidence of delayed bleeding after ESD in 10,320 patients with
early-stage gastric cancer resected by ESD between November 2013 and January 2016 at 33
Japanese institutions and investigated risk factors for delayed bleeding in elderly patients older
than 80 years.
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RESULTS: The incidence of delayed bleeding in elderly patients older than 80 years was 5.7% (95% confidence
interval [CI]: 4.6%–6.9%,95/1,675), whichwas significantly higher than that in nonelderly (older than
20 years and younger than 80 years) patients (4.5%, 4.1%–5.0%, 393/8,645). Predictive factors for
ESD-associated bleeding differed between nonelderly and elderly patients. On multivariate analysis of
predictive factors at the time of treatment, risk factors in elderly patients were hemodialysis (odds ratio:
4.591, 95% CI: 2.056–10.248, P < 0.001) and warfarin use (odds ratio: 4.783, 95% CI:
1.689–13.540, P5 0.003).
DISCUSSION: Thismulticenter study found that the incidence of delayed bleeding after ESD in Japanese patients older
than80 yearswas high, especially in patients receiving hemodialysis and takingwarfarin.Management of
ESD to prevent delayed bleeding requires particular care in patients older than 80 years.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A690
Clinical and Translational Gastroenterology 2021;12:e00404. https://doi.org/10.14309/ctg.0000000000000404
INTRODUCTION
Gastric cancer (GC), one of the major types of cancers, is par-
ticularly prevalent in East Asian countries such as Japan, Korea,
and China. Indeed, against a world age-standardized incidence
rate per 100,000 persons in 2012 of 12.1 (17.4 in men and 7.5 in
women), the age-standardized incidence rate for Korea in 2018
was 39.6, followed by 27.5 in Japan, and 20.7 in China (1). Among
treatments, endoscopic submucosal dissection (ESD) was de-
veloped as an endoscopic procedure for early-stage GC (2). ESD
provides complete but minimally invasive pathological assess-
ment and is generally selected as the first-line treatment for early-
stage GC (2). However, several lesion-related factors can prolong
procedure time. These include a large lesion size and the presence
within the lesion of ulceration, scarring, and fibrosis. These in
turn are considered to increase the risk of adverse events, such as
delayed bleeding and perforation (3–5). Moreover, several
procedure-related factors also influence procedure time and the
incidence of adverse events, including type of knife and co-
agulation mode and endoscopist experience (3–7). Of the many
possible factors affecting bleeding after ESD for GC, antith-
rombotic drugs are regarded as a major risk factor (8,9).
The proportion of the world’s population older than 60 years
will nearly double between 2015 and 2050, from 12% (900 mil-
lion) to 22% (2 billion). The World Health Organization defines
people aged 65–74 years as early-stage elderly population and
those aged 75 years or older as late-stage elderly population. Over
the past 2 decades, the elderly population of Japanese aged 85
years or older has increased from 1.4 to 4.8 million, or from 1.2%
to 3.8%of the total (10). The number of elderly patients older than
80 years withGC in Japan has also increased. Elderly patientsmay
be more likely to experience severe adverse events than non-
elderly patients, including delayed bleeding after ESD because of
physical weakness, poor general condition, comorbidities, and a
generally higher intake of several drugs, including antithrombotic
and nonsteroidal antiinflammatory agents (11). Accordingly, the
efficacy and safety of ESD in elderly patients warrants particular
consideration. Because elderly patients are generally at higher risk
of multicausal death, the need for ESD in the elderly patients
should consider both efficacy and safety and whether the risk
factors of adverse events after ESD are similar to those of non-
elderly patients.
In this study, we conducted a retrospective multicenter trial of
Japanese elderly patients with early-stage GC treated at 33 Japa-
nese institutions (12). This study was conducted as a subanalysis
of our previous study (12) and had 2 goals: evaluating the in-
cidence of ulcer bleeding after ESD for GC in elderly patients
older than 80 years and clarifying risk factors of ESD-associated
delayed bleeding at the time of treatment.
METHODS
Study design and patients
We retrospectively enrolled 11,452 patients who were scheduled
to undergo ESD for early-stage GC at 33 Japanese institutions
between November 2013 and October 2016 (12). Inclusion cri-
teria were patient aged 20 years or older and early-stage GC
clinically diagnosed. Patients were excluded if they failed to
complete ESD endoscopically and pathologically, had a follow-up
duration of ,28 days after ESD, underwent closure of an ulcer
after ESD, received polyglycolic acid (PGA) sheets and fibrin glue
after ESD, received additional photodynamic therapy after ESD,
refused the use of their clinical data, had invasion to the mus-
cularis propria or deeper, or had remnant stomach. The criteria
used to diagnose early-stage GC for ESD were consistent with
Japanese GC treatment guidelines (13,14). Patients with intra-
operative bleeding during the ESD procedure were included.
The study protocol conformed to the ethical guidelines of the
Declaration of Helsinki and was reviewed and approved by the
Institutional ReviewBoard of each institution before recruitment.
This study was conducted as a subanalysis of our previous
study (12).
ESD for GC
ESD for early-stage GC was performed based on a standard ESD
procedure at all institutions. The type of endoscope, knife used as the
cutting device, and electrosurgical generator used during the endo-
scopic treatment depended on the institution. A scheduled second-
look endoscopic procedure also depended on the institution.
In patients taking antithrombotic drugs, most ESDs were
performed according to guidelines for gastroenterological en-
doscopy in patients undergoing antithrombotic treatment pub-
lished by the Japan Gastroenterological Endoscopy Society (15).
Definition of bleeding
We defined post-ESD delayed bleeding as gastric bleeding with
clinical signs (e.g., hematemesis, melena, and bloody stool) con-
firmed by emergency endoscopy within 28 days post-ESD.
Clinical symptoms were defined as hematemesis, melena, or a









decrease in hemoglobin of .2 g/dL since the most recent labo-
ratory test.
Statistical analysis
Values for age, hospital stay duration, and tumor size are given as
the mean 6 SD. Categorical variables were summarized as
numbers and percentages, and statistically significant differences
in category variables between the 2 groups (nonelderly patients
older than 20 years and younger than 80 years vs elderly patients
older than 80 years) were determined by the x2 test. Statistically
significant differences in mean values between the 2 groups were
determined by the t test. Multivariate logistic regression analyses
were used to test the associations of 16 candidate variables with
bleeding after ESD for early-stage GC at the time of treatment.
Multicollinearity among variables was tested using the variance
inflation factor. P, 0.05 was considered statistically significant,
and all P values were 2-sided. Calculations were conducted using
SPSS version 26 (IBM, Armonk, NY). All authors had access to
the study data and reviewed and approved the final manuscript.
RESULTS
Patient characteristics
We enrolled a total of 11,452 patients with GC resected by ESD at
33 institutions (Figure 1). Of these, 1,132 patients met an exclu-
sion criterion and were excluded, namely failure to complete ESD
(n 5 22), follow-up duration of ,28 days after ESD (n 5 240),
PGA sheet or closure of ulcer after ESD (n5 401), refusal to the
use of clinical data (n 5 14), photodynamic therapy after ESD
(n5 4), invasion of themuscularis propria or deeper (n5 6), and
remnant stomach (n 5 445). Finally, we analyzed the data of a
total of 10,320 patients. No patient experienced cancellation of
ESD or required surgery due to massive intraoperative bleeding
during the ESD procedure.
Among clinical characteristics, the mean age was 71.7 6 9.1
years, and the percentage of men was 74.2% (Table 1). Antith-
rombotic drugs were used by 18.0% of patients (1,860/10,320)
and antiplatelet drugs and anticoagulants by 13.8% (1,428/
10,320) and 5.6% (579/10,320) of patients, respectively. Re-
garding adverse events, the incidence of delayed bleeding and
perforation was 4.7% and 1.5%, respectively (Table 1).
The incidence of bleeding after ESDwas significantly higher in
patients with comorbidities, use of antithrombotic drugs, re-
placement of an antithrombotic drug with aspirin or cilostazol,
interruption of an antithrombotic drug, and heparin bridging
(Table 2). Patients with multiple tumors, lesions located in the
lower third of the stomach, and a tumor size .30 mm had a
significantly increased incidence of bleeding. AmongESD-related
factors, a procedure time of.120 minutes was associated with a
significantly increased incidence of bleeding (Table 2). No patient
required surgery or died due to delayed bleeding after ESD.
Transfusion was performed in 1.4% (143/10,320) of all patients,
1.3% (111/8,645) of nonelderly patients, and 1.9% (32/1,675) of
elderly patients (Table 2).
GC patients receiving ESD between nonelderly and
elderly populations
Although the World Health Organization defines people aged
65–74 years as early-stage elderly, we divided patients into 2
groups: nonelderly patients aged older than 20 years and younger
than 80 years (n5 8,645) and elderly patients older than 80 years
(n 5 1,675). Rates of patients with ischemic heart disease and
hemodialysis and use of antithrombotic drugs, antiplatelet drugs
Figure 1.Workflow for patient enrollment to investigate the incidence of delayed bleeding after endoscopic submucosal dissection (ESD).
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(aspirin, cilostazol, and thienopyridine), and anticoagulants
(warfarin) were significantly higher in the elderly than those in
the nonelderly patients (Table 1). Lesion characteristics, such as
location in the stomach, differentiated type of tumor, and tumor
size, were significantly different between the 2 groups, whereas
procedure-related factors, such as procedure time and en block
resection rate, were similar. Among adverse events, the incidence
of bleeding in the elderly patients was 5.7%, which was signifi-
cantly higher than that in the nonelderly patients (4.5%) (P 5
0.037) (Table 1).




than 80 yr (n5 8,645)
Elderly patients, older
than 80 yr (n5 1,675) P
Demographic
Age, yr, mean 6 SE 71.7 6 9.1 69.3 6 7.9 83.9 6 2.6 ,0.001
Men, n (%) 7,660 (74.2) 6,533 (75.6) 1,127 (67.3) ,0.001
Comorbidities
Ischemic heart disease, n (%) 730 (7.1) 550 (6.4) 180 (10.7) ,0.001
Liver cirrhosis, n (%) 192 (1.9) 158 (1.8) 34 (2.0) 0.575
Hemodialysis, n (%) 155 (1.5) 115 (1.3) 40 (2.4) 0.001
AT therapy, n (%) 1,860 (18.0) 1,376 (15.9) 484 (28.9) ,0.001
APA, n (%) 1,428 (13.8) 1,041 (12.0) 387 (23.1) ,0.001
Aspirin, n (%) 981 (9.5) 722 (8.4) 259 (15.5) ,0.001
Cilostazol, n (%) 236 (2.3) 166 (1.9) 70 (4.2) ,0.001
Thienopyridine, n (%) 460 (4.5) 345 (4.0) 115 (6.9) ,0.001
Anticoagulant drug, n (%) 579 (5.6) 445 (5.1) 134 (8.0) ,0.001
Warfarin, n (%) 326 (3.2) 238 (2.8) 88 (5.3) ,0.001
DOAC, n (%) 253 (2.5) 207 (2.4) 46 (2.7) 0.394
Interruption of AT agents, n (%) 1,406 (13.6) 1,034 (12.0) 372 (22.2) ,0.001
One kind of AT agent, n (%) 1,215 (11.8) 887 (10.3) 328 (19.6) ,0.001
Two kinds of AT agent, n (%) 181 (1.8) 1,422 (1.6) 39 (2.3)
Three kinds of AT agent, n (%) 10 (0.1) 5 (0.1) 5 (0.3)
Replacement of APAs, n (%) 121 (1.2) 83 (1.0) 38 (2.3) ,0.001
Heparin bridging, n (%) 429 (4.2) 322 (3.7) 107 (6.4) ,0.001
Lesion
Multiple tumors, n (%) 1,294 (12.5) 1,053 (12.2) 241 (14.4) 0.013
Location in lower third of stomach, n (%) 4,688 (45.4) 3,860 (44.7) 828 (49.4) ,0.001
Predominance of undifferentiated type, n (%) 506 (4.9) 469 (5.4) 37 (2.2) ,0.001
Tumor size, mm, mean 6 SE 17.7 6 12.5 17.4 6 12.2 19.4 6 13.9 ,0.001
Invasion to SM2, n (%) 655 (6.3) 535 (6.2) 120 (7.2) 0.134
Ulceration (scar), n (%) 977 (9.5) 813 (9.4) 164 (9.8) 0.631
Procedure
Procedure time .120 min, n (%) 1,886 (18.3) 1,570 (18.2) 316 (19.0) 0.453
En block resection, n (%) 10,261 (99.4) 8,599 (99.5) 1,662 (99.2) 0.225
Second-look endoscopy, n (%) 7,384 (71.6) 6,128 (70.9) 1,256 (75.0) 0.001
Use of antacid drug (PPI/P-CAB/H2RA), n (%) 10,303 (99.8) 8,632 (99.8) 1,671 (99.8) 0.414
Bleeding, n (%) 489 (4.7) 393 (4.5) 96 (5.7) 0.037
Perforation, n (%) 154 (1.5) 127 (1.2) 27 (1.6) 0.802
Hospital stay duration, d, mean 6 SE 7.06 4.0 6.9 6 3.7 7.5 6 5.2 ,0.001
P: statistical difference between nonelderly and elderly patients.
APA, antiplatelet agent; AT, antithrombotic; DOAC, direct oral anticoagulant; ESD, endoscopic submucosal dissection; H2RA, histamine 2 receptor antagonist; P-CAB,
potassium-competitive acid blocker; PPI, proton pump inhibitor; SM2, submucosal invasion $500 mm from the muscularis mucosa.









Table 2. Numbers and rates of delayed bleeding after ESD in nonelderly and elderly patients
Total (n5 10,320) Nonelderly patients, £80 yr (n 5 8,645) Elderly patients, >80 yr (n5 1,675)
PWith factor Without factor P* With factor Without factor P* With factor Without factor P*
Comorbidities
Ischemic heart disease, n (%) 102/730 (14.0) 387/9,590 (4.0) ,0.001 84/550 (15.3) 309/8,095 (3.8) 0.001 18/180 (10.0) 78/1,495 (5.2) 0.016 0.119
Liver cirrhosis, n (%) 14/192 (7.3) 475/10,128 (4.7) 0.118 12/158 (7.6) 381/8,847 (4.5) 0.079 2/34 (5.9) 94/1,641 (5.7) 1.000 0.745
Hemodialysis, n (%) 36/155 (23.2) 453/10,165 (4.5) ,0.001 27/115 (23.5) 366/8,530 (4.3) ,0.001 9/40 (22.5) 87/1,635 (5.3) ,0.001 0.921
AT therapy, n (%) 222/1,860 (11.9) 267/8,460 (3.2) ,0.001 177/1,376 (12.9) 216/7,629 (3.0) ,0.001 45/484 (9.3)/ 51/1,191 (4.3) ,0.001 0.063
APA, n (%) 155/1,428 (10.9) 334/8,892 (3.8) ,0.001 122/1,041 (11.7) 271/7,604 (3.6) ,0.001 33/387 (8.5) 63/1,288 (4.9) 0.009 0.120
Aspirin, n (%) 110/981 (11.2) 379/9,339 (4.1) ,0.001 88/722 (12.2) 305/7,923 (3.8) ,0.001 22/259 (8.5) 74/1,416 (5.2) 0.042 0.145
Cilostazol, n (%) 20/236 (8.5) 469/10,084 (4.7) 0.012 13/166 (7.8) 380/8,479 (4.5) 0.050 7/70 (10.0) 89/1,605 (5.5) 0.116 0.617
Thienopyridine, n (%) 67/460 (14.6) 422/9,860 (4.3) ,0.001 56/345 (16.2) 337/8,300 (4.1) ,0.001 11/115 (9.6) 85/1,560 (5.4) 0.091 0.124
Anticoagulant drug, n (%) 111/579 (19.2) 378/9,741 (3.9) ,0.001 91/445 (20.4) 302/8,200 (3.7) ,0.001 20/134 (14.9) 76/1,541 (4.9) ,0.001 0.235
Warfarin, n (%) 68/326 (20.9) 421/9,994 (4.2) ,0.001 52/238 (21.8) 341/8,407 (4.1) ,0.001 16/88 (18.2) 80/1,587 (5.0) ,0.001 0.556
DOAC, n (%) 43/253 (17.0) 446/10,067 (4.4) ,0.001 39/207 (18.8) 354/8,438 (4.2) ,0.001 4/46 (8.7) 92/1,629 (5.6) 0.332 0.151
Interruption of AT agents, n (%) 175/1,406 (12.4) 314/8,911 (3.5) ,0.001 140/1,034 (13.5) 253/7,608 (3.3) ,0.001 35/372 (9.4) 61/1,303 (4.7) 0.001 0.065
One kind of AT agent, n (%) 137/1,215 (11.3) 314/8,911 (3.5) ,0.001 108/887 (12.2) 253/7,608 (3.3) ,0.001 29/328 (8.8) 61/1,303 (4.7) ,0.001 0.142
Two kinds of AT agent, n (%) 34/181 (18.8) 314/8,911 (3.5) 29/142 (20.4) 253/7,608 (3.3) 5/39 (12.8) 61/1,303 (4.7)
Three kinds of AT agent, n (%) 4/10 (40.0) 314/8,911 (3.5) 3/5 (60.0) 253/7,608 (3.3) 1/5 (20.0)/ 61/1,303 (4.7)
Replacement of APAs, n (%) 14/121 (11.6) 475/10,198 (4.7) 0.002 10/83 (12.0) 383/8,561 (4.5) 0.004 4/38 (10.5) 92/1,637 (5.6) 0.273 0.824
Heparin bridging, n (%) 77/429 (17.9) 412/9,891 (4.2) ,0.001 63/322 (19.6) 330/8,323 (4.0) ,0.001 14/107 (13.1)/ 82/1,568 (5.2) 0.004 0.200
Lesion
Multiple tumors, n (%) 83/1,294 (6.4) 406/9,026 (4.5) 0.003 63/1,053 (6.0) 330/7,592 (4.3) 0.022 20/241 (8.3) 76/1,434 (5.3) 0.072 0.218
Location in lower third of
stomach, n (%)
270/4,688 (5.8) 219/5,632 (3.9) ,0.001 213/3,860 (5.5) 180/4,785 (3.8) ,0.001 57/828 (6.9) 39/847 (4.6) 0.046 0.150
Undifferentiated type, n (%) 26/506 (5.1) 463/9,814 (4.7) 0.677 22/469 (4.7)/ 371/8,176 (4.5) 0.820 4/37 (10.8) 92/1,638 (5.6) 0.158 0.132
Tumor size (.30 mm), n (%) 84/1,217 (6.9) 405/9,103 (4.4) ,0.001 66/982 (6.7) 327/7,663 (4.3) 0.001 18/235 (7.7) 78/1,440 (5.4) 0.173 0.635
Invasion to SM2, n (%) 39/655 (6.0) 450/9,664 (4.7) 0.125 30/535 (5.6) 363/8,109 (4.5) 0.237 9/120 (7.5)/ 87/1,555 (5.6) 0.411 0.458
Ulceration (scar), n (%) 51/977 (5.2) 437/9,320 (4.7) 0.479 39/813 (4.8) 353/7,811 (4.5) 0.723 12/164 (7.3) 84/1,508 (5.6) 0.375 0.212
Procedure
Procedure time .120 min, n (%) 112/1,886 (5.9) 375/8,411 (4.5) 0.007 90/1,570 (5.7) 302/7,061 (4.3) 0.016 22/316 (7.0) 73/1,350 (5.4) 0.282 0.428
En block resection, n (%) 486/10,259 (4.7) 3/61 (4.9) 0.765 391/8,597 (4.5) 2/48 (4.2) 0.899 95/1,662 (5.7) 1/13 (7.7) 0.537 0.051
Second-look endoscopy, n (%) 361/7,384 (4.9) 128/2,936 (4.4) 0.259 292/6,128 (4.8) 101/2,517 (4.0) 0.139 69/1,256 (5.5) 27/419 (6.4) 0.468 0.300










































In both nonelderly and elderly patients, the incidence of
bleeding was significantly higher in men; patients with ischemic
heart disease and hemodialysis; those receiving antiplatelet drugs,
aspirin, anticoagulants, or warfarin or in whom an antith-
rombotic drug was replaced with aspirin or cilostazol; and those
who underwent heparin bridging (Table 2). Among lesion-
related factors, a lesion location in the lower third of the stomach
was associatedwith a significantly increased incidence of bleeding
in both nonelderly and elderly patients. Although the factors
related to a high incidence of bleeding in the elderly and non-
elderly patients were similar, the nonelderly patients had a higher
incidence of these factors than the elderly patients.
Predictive factors showing a P value ,0.05 in univariate
analysis were included inmultivariate logistic regression analysis.
For ESD-associated bleeding at the time of treatment in non-
elderly patients aged older than 20 and younger than 80 years, risk
was increased in patients with ischemic heart disease (odds ratio
[OR]: 1.861, 95% confidence interval [CI]: 1.295–2.673), hemo-
dialysis (4.363, 2.652–7.178), aspirin (1.898, 1.332–2.702), thie-
nopyridine (3.205, 2.012–5.105), warfarin (6.945, 3.951–12.209),
and direct oral anticoagulant (DOAC) (7.934, 4.692–13.414) use,
tumor size.30 mm (1.763, 1.322–2.350), and tumor location in
the lower third (1.597, 1.287–1.981) (Table 3).
In univariate analysis in elderly patients older than 80 years,
predictive factors for bleeding after ESD were ischemic heart
disease (OR: 2.019, 95% CI: 1.179–3.456), hemodialysis (5.166,
2.385–11.189), aspirin (1.683, 1.026–2.763) and warfarin (4.186,
2.329–7.526) use, heparin bridging (2.727, 1.491–4.992), and
tumor location (1.532, 1.007–2.329) (Table 4). On multivariate
logistic regression analysis in elderly patients, the only risk factors
were hemodialysis (OR: 4.591, 95% CI: 2.056–10.248, P, 0.001)
and warfarin use (OR: 4.783, 95% CI: 1.689–13.540, P 5 0.003)
(Table 4).
Hospital stay duration in nonelderly and elderly patients with
delayed bleeding after ESD was 10.4 6 7.0 days and 10.4 6 6.1
days, whereas that in nonelderly and elderly patients without
delayed bleeding was 6.8 6 3.7 days and 7.3 6 5.1 days, re-
spectively. There was no significant difference of hospital stay
duration between nonelderly and elderly patients.
Predictive factors for ESD-associated bleeding in
different generations
To evaluate the incidence of bleeding after ESD in different
generations and to clarify risk factors at the time of treatment, we
divided patients into 4 groups: 20–40 years, 40–60 years, 60–80
years, and older than 80 years (see Supplementary Tables 1 and 2,
Supplementary Digital Content 1, http://links.lww.com/CTG/
A690). Regarding characteristics of GC, the rate of the un-
differentiated type in patients aged 20–40 years was 53.2%. The
use of antithrombotic drugs in patients aged 60–80 years and
older than 80 years was higher than in younger generations. On
univariate analysis, although risk for bleeding was significantly
increased in the patients aged 40–60 years and DOAC use, no
significant association with other drugs was seen (see Supple-
mental Table 2, Supplementary Digital Content 1, http://links.
lww.com/CTG/A690).
DISCUSSION
In elderly patients older than 80 years, judgment of whether
medication and treatmentwill improve prognosis requires careful



















































































































































































































































































































































































































































































































of GC patients older than 80 years has recently increased in Japan
with the aging of society, evaluation of the characteristics of el-
derly GC patients and their incidence of ESD-related adverse
events is critical to identifying risk factors for adverse events.
Generally, ESD is technically demanding and may be associated
with severe complications. It requires training and experience
with a positive attitude to learning that improves skill and min-
imizes unwanted complications. This study was a retrospective
multicenter observational study that included more than 10,000
patients undergoing ESD from Japanese endoscopists who were
experienced and skilled in this procedure. The incidence of
bleeding after ESD in patients older than 80 years of 5.7% (95%
CI: 4.6%–6.9%) was significantly higher than the 4.5% (95% CI:
4.1%–5.0%) in patients younger than 80 years. Patients older than
80 years have a wider range of possible factors associated with
bleeding after ESD than those younger than 80 years, including
hemodialysis, use of antiplatelet drugs, aspirin, thienopyridine,
anticoagulant drugs, and warfarin, multiple tumors, tumor size
.30 mm, and tumor location in the lower third of the stomach
(Table 1). Accordingly, they require attention to the possibility of
adverse events, particularly those receiving hemodialysis and
taking warfarin.
Incidence of delayed bleeding after ESD in elderly patients
GC is the third most common cancer diagnosed worldwide in
men and the third leading cause of cancer-related death in men,
affecting approximately 1 million new individuals each year and
causing at least 700,000 deaths (15,16). National GC screening
programs using endoscopy in Korea and Japan may have con-
tributed to a decrease in GC mortality by decreasing diagnosis at
an advanced stage and byHelicobacter pylori eradication therapy
after endoscopy (17). In Japan, although approximately 50,000
GC deaths occurred annually over the past 40 years, deaths have
lately significantly decreased, from 50,136 in 2010 to 42,931 in
2019, after the expansion of insurance coverage to include erad-
ication therapy (18,19). However, given the increased life ex-
pectancy of Japanese, the number of GC deaths in Japanese
patients aged 80 years or older and with GC has also increased,
from 19,983 in 2010 to 21,284 in 2019 (19). In patients older than
80 years, although endoscopic and surgical procedures for GC
were previously often avoided because of age, severe comorbid-
ities, and low activities of daily living scores, recent improvement
in life expectancy has increased the number of patients suitable
for such procedures.
Among adverse events, reported rates of bleeding after ESD
for GC range from 4.1% to 8.5% of patients (8,9,20,21). A recent
meta-analysis reported a pooled rate of bleeding of 5.1% (95%CI:
4.5%–5.7%) (22) and suggested a number of possible factors,
including male sex, cardiopathy, antithrombotic drugs, liver
cirrhosis, chronic kidney disease, tumor size . 20 mm, resected
specimen size . 30 mm, location in the lesser curvature, flat/
depressed type, histology, and ulceration. This meta-analysis also
reported that a patient’s age of 75 years or older is not a risk factor
for bleeding (22). Watanabe et al. (23) reported that there was no
significant difference in the incidence of bleeding among different
age groups (patients aged 85 years or older [4.2%], patients aged
65–84 years [4.8%], and patients aged 64 years or younger
[6.2%]), as was also observed in other reports of patients aged
$75 years (24–27). These reports had small sample sizes, how-
ever, leaving 2 questions unanswered, namely whether the in-
cidence of bleeding after ESD was similar between the nonelderly
and elderly populations and what risk factors were characteristic
Table 3. Univariate andmultivariate logistic regression analysis of predictive factors for ESD-associated bleeding at the time of treatment in
nonelderly patients
Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Sex Men 1.633 1.248–2.138 ,0.001 1.258 0.951–1.663 0.108
Ischemic heart disease Yes 4.542 3.507–5.883 ,0.001 1.861 1.295–2.673 0.001
Liver cirrhosis Yes 1.749 0.962–3.178 0.067
Hemodialysis Yes 6.844 4.391–10.666 ,0.001 4.363 2.652–7.178 ,0.001
Aspirin Yes 3.467 2.698–4.454 ,0.001 1.898 1.332–2.702 ,0.001
Cilostazol Yes 1.811 1.019–3.220 0.043 1.400 0.736–2.663 0.305
Thienopyridine Yes 4.579 3.371–6.219 ,0.001 3.205 2.012–5.105 ,0.001
Warfarin Yes 6.613 4.773–9.162 ,0.001 6.945 3.951–12.209 ,0.001
DOAC Yes 5.301 3.683–7.631 ,0.001 7.934 4.692–13.414 ,0.001
Interruption of AT agents Yes 4.553 3.661–5.660 ,0.001 0.709 0.454–1.107 0.130
Replacement of APAs Yes 2.925 1.499–5.709 0.002 0.760 0.350–1.651 0.488
Heparin bridging Yes 5.892 4.380–7.925 ,0.001 1.011 0.622–1.643 0.965
Number of tumors Multiple 1.400 1.061–1.848 0.017 1.251 0.932–1.681 0.136
Tumor size .30 mm 1.616 1.230–2.124 0.001 1.763 1.322–2.350 ,0.001
Tumor location Lower third 1.494 1.219–1.831 ,0.001 1.597 1.287–1.981 ,0.001
Tumor differentiation Undifferentiated 1.035 0.667–1.609 0.877
APA, antiplatelet agent; AT, antithrombotic; CI, confidence interval; DOAC, direct oral anticoagulant; ESD, endoscopic submucosal dissection; OR, odds ratio.
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for bleeding in elderly patients undergoing ESD. In this multi-
center study, the rate of bleeding in elderly patients older than 80
years was 5.7% (96/1,675), which was significantly higher than
that in nonelderly patients (4.5%, 393/8,645). Considered to-
gether with 3 additional factors—the incidence of bleeding in
patients older than 80 years was not 2–3 times greater than that in
nonelderly patients; the higher incidence of general possible risk
factors for bleeding in patients older than 80 years, such as use of
antithrombotic drugs; and the fact that patients without such risk
factors also had high rate of bleeding—our findings indicate the
need for more careful management of ESD to prevent bleeding in
patients older than 80 years.
In this study, although we excluded 401 patients having use of
a PGA sheet or clip closure of ulcers after ESD (3.5%), these
practices are no longer common (28,29). However, clip closure is
common after endoscopic mucosal resection, and the use of en-
doscopic closure after ESD has been reported to prevent delayed
bleeding (30). In addition, the tissue-shielding method using a
PGA sheet is also used to prevent delayed bleeding after ESD in
patients at high risk for delayed bleeding (31). Therefore, further
study to clarify the efficacy of ulcer closure and tissue-shielding
method should include these patients.
Risk factors of delayed bleeding after ESD in elderly patients
Risks of bleeding after ESD can be classified into several cate-
gories, including patient-related, medication-related, lesion-
related and procedure-related factors, and acid inhibitory drugs
(6,22,32). Accurate identification of risks among these categories
can help to guide management after ESD, especially in patients
with high risk. We previously developed a prediction model
(Bleeding after Endoscopic Submucosal dissection Trend from
Japan [BEST-J] score) for bleeding after ESD for GC, which was
derived from a combination of 10 variables (12). Rates of bleeding
at low (0–1 points), intermediate (2 points), high (3–4 points),
and very high risk ($5 points) were 2.8%, 6.1%, 11.4%, and
29.7%, respectively (12). In this study, when we divided patients
into nonelderly and elderly patients, aged younger than 80 and
older than 80 years, respectively, most of the risk factors for
bleeding were similar between the 2 groups, and no specific new
risk factors were identified (22). In addition, surprisingly, al-
though the rate of bleeding in patients older than 80 years was
significantly higher than that in patients younger than 80 years,
major risks (e.g., antithrombotic drugs, DOAC, heparin bridging,
and location and size of lesion) did not increase the risk of
bleeding. A prediction model using the BEST-J score in patients
aged 85 years or older showed modest discrimination, with a c
statistic of 0.65 (95% CI: 0.55–0.75), which was lower than that in
the nonelderly population. This may be because the rate of
bleeding in patients without major risks is relatively high. A
follow-on study should investigate whether the BEST-J score
should be selected as a predictionmodel for bleeding after ESD for
GC in patients older than 80 years.
Limitations
This study has several limitations. First, it was conducted under a
retrospective design. Second, all patients were Japanese, and it is
unclearwhether elderly patients in other populations have similar
characteristics for bleeding. Third, we did not analyze survival
rates in patients with early-stage GC between those who un-
derwent ESD and those who did not. Further prospective studies
are necessary to confirm the safety and efficacy of ESD for GC in
patients older than 80 years.
Table 4. Univariate andmultivariate logistic regression analysis of predictive factors for ESD-associated bleeding at the time of treatment in
elderly patients
Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Sex Men 1.330 0.838–2.111 0.227
Ischemic heart disease Yes 2.019 1.179–3.456 0.010 1.422 0.735–2.751 0.296
Liver cirrhosis Yes 1.029 0.243–4.357 0.969
Hemodialysis Yes 5.166 2.385–11.189 ,0.001 4.591 2.056–10.248 ,0.001
Aspirin Yes 1.683 1.026–2.763 0.039 1.370 0.753–2.492 0.303
Cilostazol Yes 1.893 0.842–4.253 0.122
Thienopyridine Yes 1.835 0.950–3.547 0.071
Warfarin Yes 4.186 2.329–7.526 ,0.001 4.783 1.689–13.540 0.003
DOAC Yes 1.591 0.558–4.522 0.385
Interruption of AT agents Yes 1.503 0.909–2.484 0.112
Replacement of APAs Yes 1.976 0.686–5.686 0.207
Heparin bridging Yes 2.727 1.491–4.992 0.001 0.755 0.257–2.217 0.609
Number of tumors Multiple 1.617 0.968–2.700 0.168
Tumor size .30 mm 1.448 0.851–2.466 0.172
Tumor location Lower third 1.532 1.007–2.329 0.046 1.408 0.918–2.161 0.117
Tumor differentiation Undifferentiated 2.037 0.707–5.872 0.188
APA, antiplatelet agent; AT, antithrombotic; CI, confidence interval; DOAC, direct oral anticoagulant; ESD, endoscopic submucosal dissection; OR, odds ratio.










ESD is less invasive than open surgery and improves quality of life
in patients with early-stage GC. In this nationwide multicenter
study in elderly Japanese older than 80 years, the incidence of
bleeding after ESD was high, especially in patients receiving he-
modialysis and taking warfarin.
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